- recruitingPHASE1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
This study is testing a new medicine called ION464 for Multiple System Atrophy (MSA). It's looking at how safe the medicine is, if people can tolerate it, and how it moves through the body. This is a first step to see if ION464 could help people with MSA.
Austria · France · Germany - active not recruitingPHASE3
A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)
This study is testing a new medicine, Amlenetug, for Multiple System Atrophy (MSA). We want to see if it's safe and helps people with MSA. Some people will get the medicine, and others will get a dummy treatment to compare.
United States · Australia · Canada - recruitingNA
The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders
This study looks into how a new wearable device, CUE1, might help people with Parkinson's disease and similar conditions. It aims to improve common symptoms like movement difficulties and tiredness, and check if the device is safe and easy to use.
United Kingdom - recruiting
Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes
This study looks at how people with rare brain conditions like PSP, CBD, and MSA use healthcare services and how this affects their quality of life. It aims to understand which NHS services are most helpful.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
Open-Label Extension Study to Provide Access to ATH434 in Patients with Multiple System Atrophy
This study is looking at a new medicine called ATH434 for people with Multiple System Atrophy (MSA). It's checking if the medicine is safe and if people can take it for a long time. Researchers will observe side effects and monitor general health.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy
This study is testing a new medicine, TAK-341, for Multiple System Atrophy (MSA). Researchers want to see if it's safe, and if it can help improve symptoms of MSA over 52 weeks, compared to a dummy treatment.
Denmark · Italy · Portugal - authorisedTherapeutic use (Phase IV)
(ASK-PD0-CS002) Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants with Parkinson’s Disease or Multiple System Atrophy
This study is checking on people who previously received a special gene therapy (AAV2-GDNF) for Parkinson's disease or Multiple System Atrophy. It aims to understand how safe and effective the treatment has been for them over a long time, looking at any side effects and how their symptoms are managed.
Poland - recruiting
Synaptic Loss in Multiple System Atrophy
This study looks at brain changes in Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP). Researchers want to understand how brain connections called synapses are affected in MSA and how a protein called tau builds up in PSP.
United Kingdom